


PRODUCT INFORMATION



Xanomeline (oxalate)

Item No. 10790

CAS Registry No.: 141064-23-5
Formal Name: 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-pyridine, ethanedioate
Synonyms: Lumeron, LY246708, Memcor
MF: C₁₄H₂₃N₃OS • C₂H₂O₄
FW: 371.5
Purity: ≥95%
UV/Vis.: λ_{max}: 223, 296 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Xanomeline (oxalate) is supplied as a crystalline solid. A stock solution may be made by dissolving the xanomeline (oxalate) in the solvent of choice, which should be purged with an inert gas. Xanomeline (oxalate) is soluble in dimethyl formamide (DMF). The solubility of xanomeline oxalate in DMF is approximately 1.6 mg/ml.

Xanomeline (oxalate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, xanomeline (oxalate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Xanomeline (oxalate) has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Muscarinic receptors are G protein-coupled acetylcholine receptors that play diverse roles. Xanomeline (oxalate) is a potent agonist of muscarinic acetylcholine receptors (EC₅₀ values are 0.3, 92.5, 5, 52, and 42 nM for M₁, M₂, M₃, M₄, and M₅, respectively).¹ It has antipsychotic-like activities in rats and *Cebus* monkeys.^{2,3} M₁ selective agonists, like xanomeline oxalate, enhance memory function and has utility in treating Alzheimer's Disease.⁴

References

1. Heinrich, J. N., Butera, J. A., Carrick, T., *et al.* Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M₁-preferring receptor agonists. *Eur. J. Pharmacol.* **605**, 53-6 (2009).
2. Stanhope, K. J., Mirza, N. R., Dickerdike, M. J., *et al.* The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. *J. Pharmacol. Exp. Ther.* **299**(2), 782-92 (200).
3. Anderson, M. B., Fink-Jensen, A., Peacock, L., *et al.* The muscarinic M₁/M₄ receptor agonist xanomeline exhibits antipsychotic-like activity in *Cebus apella* monkeys. *Neuropsychopharmacology* **28**(6), 1168-75 (2003).
4. Messer, W. S., Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. *J. Mol. Neurosci.* **19**(1-2), 187-93 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM